Director TitleAgeSince
Director/Board Member 75 01/10/2013
Director/Board Member - 09/01/2023
Date Insider Type Main position Quantity % Market Cap. Importance
23/11/22 Sell

Director

1,31,879 0.2369%
22/11/22
OrbiMed Advisors Private Equity
SellCompany 1,02,80,947 18.4680%
22/11/22
OrbiMed Advisors Private Equity
SellCompany 1,02,80,947 18.4680%
Change 5-day change 1-year change 3-year change Capi.($)
-99.90%-99.92% - - 580
+0.34%+1.12%+34.75%+61.06% 6.41TCr
+0.98%+2.68%+12.25%+82.98% 5.55TCr
+1.75%+2.01%+13.30%+103.69% 5.3TCr
-1.43%-1.17%+26.27%+52.86% 4.6TCr
-0.48%-2.80%+18.01%+117.99% 4.25TCr
+0.82%+1.37%+227.94%+922.41% 4.04TCr
-2.07%+42.73%+103.77%+88.74% 3.45TCr
-0.26%-2.57%+12.55%+45.18% 3.23TCr
+0.49%-1.14%+23.78%-10.34% 2.42TCr
Average -9.98%+4.29%+52.51%+162.73% 4.36TCr
Weighted average by Cap. +0.12%+3.59%+49.33%+160.59%
Logo Tricida, Inc.
Tricida, Inc. is a pharmaceutical company. The Company is focused on its investigational drug candidate, veverimer (TRC101). TRC101 is a non-absorbed, orally administered polymer designed to treat metabolic acidosis and slow CKD progression by binding and removing acid from the gastrointestinal (GI) tract. Its veverimer, is a low-swelling, spherical polymer bead that is approximately 100 micrometers in diameter, which is a single, molecular weight, crosslinked polyamine molecule. Veverimer is a single, high molecular weight, crosslinked polyamine molecule. The size of veverimer prevents systemic absorption from the GI tract. The high degree of cross-linking within veverimer limits swelling and the overall volume in the GI tract, with the goal of facilitating GI tolerability. It is conducting renal outcomes clinical trial, VALOR-CKD (TRCA-303), to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD.
Employees
57
  1. Stock Market
  2. Stocks
  3. TCDA Stock